|
π
|
PDβ1 Blockade with Cemiplimab in Advanced Cutaneous SquamousβCell Carcinoma
37 auth.
M. Migden,
D. Rischin,
C. Schmults,
A. Guminski,
A. Hauschild,
K. Lewis,
C. Chung,
L. Hernandez-Aya,
A. Lim,
A. Chang,
G. Rabinowits,
A. Thai,
L. Dunn,
B. Hughes,
N. Khushalani,
...
B. Modi,
D. Schadendorf,
Bo Gao,
F. Seebach,
Siyu Li,
Jingjin Li,
M. Mathias,
J. Booth,
K. Mohan,
E. Stankevich,
H. Babiker,
I. BraΓ±a,
M. Gil-Martin,
J. Homsi,
M. Johnson,
V. Moreno,
J. Niu,
T. Owonikoko,
K. Papadopoulos,
G. Yancopoulos,
I. Lowy,
M. Fury
|
9 |
2018 |
9
π
|
|
π
|
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.
34 auth.
J. Christensen,
Jill Hallin,
Lars D. Engstrom,
Lauren N. Hargis,
Andrew Calinisan,
Ruth Aranda,
David M Briere,
Niranjan Sudhakar,
Vickie Bowcut,
B. R. Baer,
J. Ballard,
M. Burkard,
Jay B. Fell,
J. Fischer,
G. Vigers,
...
Jenny Y. Xue,
Sole Gatto,
J. Fernandez-Banet,
A. PavlΓcek,
K. Velastegui,
R. Chao,
J. Barton,
M. Pierobon,
E. Baldelli,
Emmanuel F Patricoin,
Douglas P Cassidy,
M. Marx,
I. Rybkin,
M. Johnson,
S. Ou,
P. Lito,
K. Papadopoulos,
P. Janne,
P. Olson
|
9 |
2019 |
9
π
|
|
π
|
Phase I Study of Pembrolizumab (MK-3475; AntiβPD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
22 auth.
A. Patnaik,
S. Kang,
D. Rasco,
K. Papadopoulos,
J. Elassaiss-Schaap,
M. Beeram,
R. Drengler,
Cong Chen,
L. Smith,
G. Espino,
...
K. Gergich,
L. Delgado,
A. Daud,
Jill A. Lindia,
Xiaoyun Li,
R. Pierce,
J. Yearley,
Dianna Y. Wu,
O. Laterza,
M. Lehnert,
R. Iannone,
A. Tolcher
|
9 |
2015 |
9
π
|
|
π
|
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
24 auth.
A. Patnaik,
L. Rosen,
S. Tolaney,
A. Tolcher,
J. Goldman,
L. Gandhi,
K. Papadopoulos,
M. Beeram,
D. Rasco,
J. Hilton,
...
A. Nasir,
R. Beckmann,
A. Schade,
Angie D. Fulford,
Tuan S. Nguyen,
R. Martinez,
P. Kulanthaivel,
Lily Q. Li,
Martin Frenzel,
D. Cronier,
E. Chan,
K. Flaherty,
P. Wen,
G. Shapiro
|
9 |
2016 |
9
π
|
|
π
|
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
18 auth.
T. Yap,
Li Yan,
A. Patnaik,
I. Fearen,
D. Olmos,
K. Papadopoulos,
R. Baird,
L. Delgado,
Adekemi Taylor,
L. Lupinacci,
...
R. Riisnaes,
L. Pope,
S. P. Heaton,
G. Thomas,
M. Garrett,
D. Sullivan,
J. D. de Bono,
A. Tolcher
|
8 |
2011 |
8
π
|
|
π
|
A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
15 auth.
Luis E. Raez,
K. Papadopoulos,
A. Ricart,
E. Chiorean,
R. DiPaola,
Mark N. Stein,
Caio M. Rocha Lima,
James J. Schlesselman,
K. Tolba,
V. Langmuir,
...
S. Kroll,
Donald T. Jung,
M. KurtoΔlu,
J. Rosenblatt,
Theodor J. Lampidis
|
8 |
2013 |
8
π
|
|
π
|
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
15 auth.
Toshio Shimizu,
A. Tolcher,
K. Papadopoulos,
M. Beeram,
D. Rasco,
L. Smith,
S. Gunn,
L. Smetzer,
T. Mays,
B. Kaiser,
...
M. Wick,
Cathy Alvarez,
Aracely Cavazos,
G. Mangold,
A. Patnaik
|
8 |
2012 |
8
π
|
|
π
|
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
30 auth.
B. Sikic,
N. Lakhani,
A. Patnaik,
Sumit A Shah,
S. Chandana,
D. Rasco,
A. Colevas,
T. O'rourke,
S. Narayanan,
K. Papadopoulos,
G. Fisher,
V. Villalobos,
Susan S. Prohaska,
M. Howard,
M. Beeram,
...
M. Chao,
B. Agoram,
J. Chen,
Jie Huang,
M. Axt,
Jie Liu,
J. Volkmer,
R. Majeti,
I. Weissman,
C. Takimoto,
D. Supan,
H. Wakelee,
Rhonda Aoki,
M. Pegram,
S. Padda
|
8 |
2016 |
8
π
|
|
π
|
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
19 auth.
V. Mazzaferro,
B. El-Rayes,
M. Droz dit Busset,
C. Cotsoglou,
W. Harris,
N. Damjanov,
G. Masi,
L. Rimassa,
N. Personeni,
F. Braiteh,
...
V. Zagonel,
K. Papadopoulos,
T. Hall,
Yunxia Wang,
B. Schwartz,
J. Kazakin,
S. Bhoori,
F. D. De Braud,
W. Shaib
|
8 |
2018 |
8
π
|
|
π
|
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
15 auth.
A. Tolcher,
J. Sarantopoulos,
A. Patnaik,
K. Papadopoulos,
ChiaβChi Lin,
J. RodΓ³n,
B. Murphy,
B. Roth,
I. McCaffery,
K. Gorski,
...
B. Kaiser,
Min Zhu,
H. Deng,
G. Friberg,
I. Puzanov
|
8 |
2009 |
8
π
|
|
π
|
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
14 auth.
S. Sandhu,
K. Papadopoulos,
P. Fong,
A. Patnaik,
C. Messiou,
D. Olmos,
George C. Wang,
B. Tromp,
T. Puchalski,
F. Balkwill,
...
B. Berns,
Shobha Seetharam,
J. Bono,
A. Tolcher
|
7 |
2013 |
7
π
|
|
π
|
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
20 auth.
A. Tolcher,
W. Messersmith,
S. Mikulski,
K. Papadopoulos,
E. Kwak,
D. Gibbon,
A. Patnaik,
G. Falchook,
A. Dasari,
G. Shapiro,
...
J. Boylan,
Zhi-xin Xu,
Ka Wang,
A. Koehler,
James X. Song,
S. Middleton,
J. Deutsch,
M. DeMario,
R. Kurzrock,
J. Wheler
|
7 |
2012 |
7
π
|
